MedPath

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
Conditions
Hidradenitis Suppurativa
Registration Number
jRCT2051240088
Lead Sponsor
Incyte Biosciences Japan G.K.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
16
Inclusion Criteria
  1. Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302).
  2. Agreement to use contraception.
  3. Willing and able to comply with the study protocol and procedures.
  4. Further inclusion criteria apply.
Exclusion Criteria
  1. Participation in the extension study could expose the participant to an undue safety risk.
  2. Women who are pregnant (or who are considering pregnancy) or breastfeeding.
  3. Further exclusion criteria apply.

Study & Design

Study Type
Interventional
Study Design
parallel assignment
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.